Sigma-Aldrich XCell Science genetically engineered iPSC-derived neural disease cells

Sigma-Aldrich has entered into an agreement with XCell Science to launch genetically engineered human neural differentiated cells and accompanying culture media developed to advance the research of neurological diseases. The products provide versatile tools for the study of central nervous system (CNS) disorders, as well as for drug screening and toxicology applications in the neural space.

The range of isogenic iPSC-derived neural cells includes APOE knockout neurons and astrocytes; MAP2 and GFAP reporter lines; and a panel for assessment of neurotoxicity and neural protective drug candidates. All cell lines have been validated by genotyping, gene expression, karyotyping and pluripotency, and have been further confirmed for their ability to differentiate into neural cells.

The genetically engineered iPSC-derived neural lines provide researchers with disease models that can contribute to deciphering the mechanism underlying the disease. The lines are said to provide more consistent disease models than currently available for assessment of compound toxicity and efficacy, which can expedite drug development.